Cover Image
市場調查報告書

移植診斷市場:分子及非分子化驗技術(血清化驗,淋巴球混合培養,PCB型,定序型),各終端用戶-全球機會分析與產業預測

Transplant Diagnostics Market by Molecular and Non-Molecular Assay Technology (Serological assay, Mixed Lymphocyte Culture, PCR Based, Sequencing Based), End-User - Global Opportunity Analysis and Industry Forecast, 2014 - 2022

出版商 Allied Market Research 商品編碼 374535
出版日期 內容資訊 英文 138 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
移植診斷市場:分子及非分子化驗技術(血清化驗,淋巴球混合培養,PCB型,定序型),各終端用戶-全球機會分析與產業預測 Transplant Diagnostics Market by Molecular and Non-Molecular Assay Technology (Serological assay, Mixed Lymphocyte Culture, PCR Based, Sequencing Based), End-User - Global Opportunity Analysis and Industry Forecast, 2014 - 2022
出版日期: 2016年09月01日 內容資訊: 英文 138 Pages
簡介

本報告提供全球移植診斷市場相關調查,彙整市場概要與今後預測,競爭趨勢,及加入此市場的主要企業簡介等資料。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 主要調查結果
  • 波特五力分析
  • 主要企業定位
  • 市場趨勢
    • 促進要素
    • 阻礙要素
    • 機會

第4章 全球移植診斷市場:各技術

  • 概要
  • 非分子化驗
    • 推動市場的要素和機會
    • 市場規模與預測
    • 血清學化驗
    • 淋巴球混合培養
  • 分子化驗
    • 市場趨勢
    • 推動市場的要素和機會
    • 市場規模與預測

第5章 全球移植診斷市場:各零件

  • 概要
  • 消耗品及試劑
  • 設備及設備
  • 軟體及服務

第6章 全球移植診斷市場:各終端用戶

  • 概要
  • 醫院·移植中心
  • 研究實驗室及學術機構
  • 商業服務供應商

第7章 全球移植診斷市場:各用途

  • 概要
  • 研究
  • 診斷

第8章 全球移植診斷市場:內臟器官別

  • 概要
  • 腎臟
  • 肝臟
  • 心臟
  • 胰臟
  • 其他

第9章 全球移植診斷市場:篩檢類別

  • 概要
  • 移植前篩檢
  • 移植後篩檢

第10章 全球移植診斷市場:各地區

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美

第11章 企業簡介

  • Immucor, Inc. (TPG Capital)
  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-la Roche AG
  • Illumina, Inc.
  • Abbott Laboratories
  • Sigma-Aldrich Corporation
  • Qiagen N.V.
  • Olerup SSP AB (Allenex)
  • DiaSorin S.P.A.

圖表

目錄
Product Code: LI 161135

Transplant diagnostics are tests that are performed pre and post-transplant procedures to check the compatibility between the donor and recipient of organ and its suitability in the body. It is mainly required to reduce the risk of organ rejection that can take place due to incompatible donors. Post-transplant, series of diagnostics tests are performed to check the chances of organ rejection.

The world transplant diagnostics market is projected to reach $1,031 million by 2022 and this growth is fueled by factors such as increasing elderly population, increased incidences of chronic disease patients, and increased focus on R&D. The market for transplant diagnostics is flanked with technological progression that is stimulated by increasing awareness related importance of organ donations. Although these factors will drive the market for transplant diagnostics there are certain elements that can limit the growth of the market. Worldwide scenario for organ shortage and difficulties in HLA sequencing can restrict the growth of the market.

The transplant diagnostics market is segmented on the basis of technology, components, application, end-users, type of organ, type of screening, and geography. The world transplant diagnostics market based on the technology is segmented into non-molecular assay and molecular assay technologies. The non-molecular assay technologies are further categorized as serological assay and Mixed Lymphocyte Culture (MLC) assay. The molecular assay technology is categorized into PCR-based and sequencing based. The global transplant diagnostics market based on the components is classified into instruments, reagents and consumables, and software and services. The transplant diagnostics market based on end-user is categorized as hospitals and transplant centers, research laboratories and academic institutes, and commercial service provider. On the bases of applications, the transplant diagnostics market is broadly classified into research and diagnostics. Further the market based on the type of organ is segmented into kidney, liver, heart, lung, pancreas, and others. On the bases of type of screening the market is categorized into pre-transplant screening and post-transplant screening. By geography the market is divided into North America, Europe, Asia Pacific and ROW including further segmentation of the major countries. The key players in the transplant diagnostics market are focused on strategies such as product approval and launches, merger and acquisition, expansion, collaboration etc. to expand their market share.

KEY BENEFITS FOR STAKEHOLDERS:

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the world transplant diagnostics market.
  • In-depth analysis has been done in this report by constructing market estimations for the key market segments between 2014 and 2022.
  • Comprehensive analysis of factors that drive and restrict the growth of the world transplant diagnostics market is provided.
  • Exhaustive analysis of the world transplant diagnostics market by technology helps in understanding the current range of the product available for commercial usage.
  • Competitive intelligence helps in understanding the competitive scenario across the geographies
  • Key market players within the world transplant diagnostics market are profiled in this report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of the market.

KEY MARKET SEGMENTS:

World transplant diagnostics market is segmented as:

By Technology

  • Non-Molecular assay
  • Serological assay
  • Mixed Lymphocyte Culture
  • Molecular assay
  • PCR Based
  • Sequencing Based

By Component

  • Instrument and Equipment
  • Reagent and consumables
  • Software and services

By End-User

  • Hospitals and transplant centers
  • Research laboratories and academic institutes
  • Commercial Service Providers

By Applications

  • Research
  • Diagnostic

By Organ Type

  • Kidney
  • Liver
  • Heart
  • Lung
  • Pancreas
  • Others

By Screening Type

  • Pre-Transplant Screening
  • Post-Transplant Screening

By Region

  • North America
    • U.S.
    • Canada
    • Mexic
    • Rest of North America
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Italy
    • Turkey
    • Rest of Europe
  • Asia-Pacific
    • Australia
    • South Korea
    • New Zealand
    • Japan
    • China
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Israel
    • Iran
    • Saudi Arabia
    • Rest of LAMEA

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key Benefits
  • 1.3. Key Market Segments
  • 1.4. Research Methodology
    • 1.4.1. Saecondary Research
    • 1.4.2. Primary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porters Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Bargaining Power of Buyers
    • 3.3.3. Threat of New Entrants
    • 3.3.4. High Intensity of Rivalry
    • 3.3.5. Threat of Substitutes
  • 3.4. Top Player Positioning, 2015
  • 3.5. Market Dynamics
    • 3.5.1. Drivers
      • 3.5.1.1. Increasing aging population
      • 3.5.1.2. Increased incidence of chronic diseases
      • 3.5.1.3. Increased focus on R&D
    • 3.5.2. Restraints
      • 3.5.2.1. organ shortage worldwide
      • 3.5.2.2. Difficulties in HLA sequencing
    • 3.5.3. Opportunities
      • 3.5.3.1. Shift from traditional methods to modern techniques for HLA typing
      • 3.5.3.2. Increasing demand for organ transplant procedures
      • 3.5.3.3. Mergers & acquisitions

CHAPTER 4: WORLD TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 4.1. Overview
    • 4.1.1. Market Size and Forecast
  • 4.2. Non-Molecular Assays
    • 4.2.1. Key Market Trends
    • 4.2.2. Key Growth Factors and Opportunities
    • 4.2.3. Market Size and Forecast
    • 4.2.4. Serological Assays
      • 4.2.4.1. Market size and forecast
    • 4.2.5. Mixed Lymphocyte Culture Assays
      • 4.2.5.1. Market size and forecast
  • 4.3. Molecular Assays
    • 4.3.1. Key Market Trends
    • 4.3.2. Key Growth Factors and Opportunities
    • 4.3.3. Market Size and Forecast
      • 4.3.3.1. PCR-based molecular assay
      • 4.3.3.2. Market size and forecast
      • 4.3.3.3. sequencing-based molecular assay
      • 4.3.3.4. Market size and forecast

CHAPTER 5: WORLD TRANSPLANT DIAGNOSTICS MARKET, BY COMPONENT

  • 5.1. Overview
  • 5.2. Consumables and Reagents
    • 5.2.1. Market Size and Forecast
  • 5.3. Instruments and Equipment
    • 5.3.1. Market Size and Forecast
  • 5.4. Software and Services
    • 5.4.1. Market Size and Forecast

CHAPTER 6: WORLD TRANSPLANT DIAGNOSTICS MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market Size and Forecast
  • 6.2. Hospitals and Transplant Centers
    • 6.2.1. Market Size and Forecast
  • 6.3. Research Laboratories and Academic Institutions
    • 6.3.1. Market Size and Forecast
  • 6.4. Commercial Service Providers
    • 6.4.1. Market Size and Forecast

CHAPTER 7: WORLD TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION

  • 7.1. Overview
  • 7.2. Research
    • 7.2.1. Market Size and Forecast
  • 7.3. Diagnostics
    • 7.3.1. Market Size and Forecast

CHAPTER 8: WORLD TRANSPLANT DIAGNOSTICS MARKET BY ORGAN TYPE

  • 8.1. Overview
  • 8.2. Kidney
    • 8.2.1. Market size and forecast
  • 8.3. Liver
    • 8.3.1. Market size and forecast
  • 8.4. Heart
    • 8.4.1. Market size and forecast
  • 8.5. Lung
    • 8.5.1. Market size and forecast
  • 8.6. Pancreas
    • 8.6.1. Market size and forecast
  • 8.7. Others
    • 8.7.1. Market size and forecast

CHAPTER 9: WORLD TRANSPLANT DIAGNOSTICS MARKET, BY TYPE OF SCREENING

  • 9.1. Overview
  • 9.2. Pretransplant Screening
    • 9.2.1. Market Size and Forecast
  • 9.3. Posttransplant Screening
    • 9.3.1. Market Size and Forecast

CHAPTER 10: WORLD TRANSPLANT DIAGNOSTICS MARKET, BY GEOGRAPHY

  • 10.1. Overview
    • 10.1.1. Market Size and Forecast
  • 10.2. North America
    • 10.2.1. Key Market Trends
    • 10.2.2. Key Growth Factors and Opportunities
    • 10.2.3. Market Size and Forecast
    • 10.2.4. U.S.: Market Size and Forecast
    • 10.2.5. Canada: Market Size and Forecast
    • 10.2.6. Mexico: Market Size and Forecast
  • 10.3. Europe
    • 10.3.1. Key Market Trends
    • 10.3.2. Key Growth Factors and Opportunities
    • 10.3.3. Market Size and Forecast
    • 10.3.4. UK: Market Size and Forecast
    • 10.3.5. Germany: Market Size and Forecast
    • 10.3.6. France: Market Size and Forecast
    • 10.3.7. Spain: Market Size and Forecast
    • 10.3.8. Italy: Market Size and Forecast
    • 10.3.9. Turkey: Market Size and Forecast
    • 10.3.10. Rest of Europe: Market Size and Forecast
  • 10.4. Asia-Pacific
    • 10.4.1. Key Market Trends
    • 10.4.2. Key Growth Factors and Opportunities
    • 10.4.3. Market Size and Forecast
    • 10.4.4. Australia: Market Size and Forecast
    • 10.4.5. South Korea: Market Size and Forecast
    • 10.4.6. New Zealand: Market Size and Forecast
    • 10.4.7. China: Market Size and Forecast
    • 10.4.8. Japan: Market Size and Forecast
    • 10.4.9. Rest of Asia-Pacific: Market Size and Forecast
  • 10.5. LAMEA
    • 10.5.1. Key Market Trends
    • 10.5.2. Key Growth Factors and Opportunities
    • 10.5.3. Market Size and Forecast
    • 10.5.4. Brazil: Market Size and Forecast
    • 10.5.5. Israel: Market Size and Forecast
    • 10.5.6. Iran: Market Size and Forecast
    • 10.5.7. Saudi Arabia: Market Size and Forecast
    • 10.5.8. Rest of LAMEA: Market Size and Forecast

CHAPTER 11: COMPANY PROFILES

  • 11.1. Immucor, Inc. (TPG Capital)
    • 11.1.1. Company overview
    • 11.1.2. Operating business segments
    • 11.1.3. Business performance
    • 11.1.4. Key strategic moves & developments
  • 11.2. Bio-Rad Laboratories, Inc.
    • 11.2.1. Company overview
    • 11.2.2. Operating business segments
    • 11.2.3. Business performance
    • 11.2.4. Key strategic moves & developments
  • 11.3. Thermo Fisher Scientific Inc.
    • 11.3.1. Company overview
    • 11.3.2. Operating business segments
    • 11.3.3. Business performance
    • 11.3.4. Key strategic moves & developments
  • 11.4. F. Hoffmann-la Roche AG
    • 11.4.1. Company overview
    • 11.4.2. Operating business segments
    • 11.4.3. Business performance
    • 11.4.4. Key strategic moves & developments
  • 11.5. Illumina, Inc.
    • 11.5.1. Company overview
    • 11.5.2. Operating business segments
    • 11.5.3. Business performance
    • 11.5.4. Key strategic moves & developments
  • 11.6. Abbott Laboratories
    • 11.6.1. Company overview
    • 11.6.2. Operating business segments
    • 11.6.3. Business performance
    • 11.6.4. Key strategic moves & developments
  • 11.7. Sigma-Aldrich Corporation
    • 11.7.1. Company overview
    • 11.7.2. Operating business segments
    • 11.7.3. Business performance
  • 11.8. Qiagen N.V.
    • 11.8.1. Company overview
    • 11.8.2. Operating business segments
    • 11.8.3. Business performance
    • 11.8.4. Key strategic moves & developments
  • 11.9. Olerup SSP AB (Allenex)
    • 11.9.1. Company overview
    • 11.9.2. Key strategic moves & developments
  • 11.10. DiaSorin S.P.A.
    • 11.10.1. Company overview
    • 11.10.2. Operating business segments
    • 11.10.3. Business performance
    • 11.10.4. Key strategic moves & developments

List of Tables

  • TABLE 1: WORLDWIDE SCENARIO FOR CHRONIC DISEASES CAUSING DEATH
  • TABLE 2: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 20152022 ($MILLION)
  • TABLE 3: TRANSPLANT DIAGNOSTICS TECHNOLOGY MARKET, BY GEOGRAPHY, 20152022 ($MILLION)
  • TABLE 4: NON-MOLECULAR ASSAYS MARKET, BY TECHNOLOGY, 20142022 ($MILLION)
  • TABLE 5: NON-MOLECULAR ASSAYS MARKET, BY GEOGRAPHY, 20142022 ($MILLION)
  • TABLE 6: SEROLOGICAL ASSAYS MARKET, BY GEOGRAPHY, 20142022 ($MILLION)
  • TABLE 7: WORLD MIXED LYMPHOCYTE CULTURE ASSAYS MARKET, BY GEOGRAPHY, 20142022 ($MILLION)
  • TABLE 8: MOLECULAR ASSAYS TECHNOLOGY MARKET, 20142022 ($MILLION)
  • TABLE 9: MOLECULAR ASSAYS MARKET, BY GEOGRAPHY, 20142022 ($MILLION)
  • TABLE 10: PCR-BASED MOLECULAR ASSAY, BY GEOGRAPHY, 20142022 ($MILLION)
  • TABLE 11: SEQUENCING-BASED MOLECULAR ASSAY, BY GEOGRAPHY, 20142022 ($MILLION)
  • TABLE 12: WORLD TRANSPLANT DIAGNOSTICS MARKET, BY COMPONENT, 20142022 ($MILLION)
  • TABLE 13: WORLD TRANSPLANT DIAGNOSTICS COMPONENT MARKET, BY GEOGRAPHY, 20142022 ($MILLION)
  • TABLE 14: WORLD TRANSPLANT CONSUMABLES MARKET, BY GEOGRAPHY, 20142022 ($MILLION)
  • TABLE 15: WORLD TRANSPLANT DIAGNOSTICS INSTRUMENTS MARKET, BY GEOGRAPHY, 20142022 ($MILLION)
  • TABLE 16: WORLD TRANSPLANT DIAGNOSTICS SOFTWARE MARKET, BY GEOGRAPHY, 20142022 ($MILLION)
  • TABLE 17: WORLD TRANSPLANT DIAGNOSTICS SERVICES MARKET, BY GEOGRAPHY, 20142022 ($MILLION)
  • TABLE 18: WORLD TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 20142022 ($MILLION)
  • TABLE 19: WORLD TRANSPLANT DIAGNOSTICS END USER MARKET, BY GEOGRAPHY, 20142022 ($MILLION)
  • TABLE 20: WORLD HOSPITALS AND TRANSPLANT CENTERS MARKET, BY GEOGRAPHY, 20142022 ($MILLION)
  • TABLE 21: WORLD RESEARCH LABORATORIES AND ACADEMIC INSTITUTIONS MARKET, BY GEOGRAPHY, 20142022 ($MILLION)
  • TABLE 22: WORLD COMMERCIAL SERVICE PROVIDERS MARKET, BY GEOGRAPHY, 20142022 ($MILLION)
  • TABLE 23: WORLD TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATIONS, 20142022 ($MILLION)
  • TABLE 24: WORLD TRANSPLANT DIAGNOSTICS APPLICATIONS MARKET, BY GEOGRAPHY, 20142022 ($MILLION)
  • TABLE 25: WORLD RESEARCH MARKET, BY GEOGRAPHY, 20142022 ($MILLION)
  • TABLE 26: WORLD DIAGNOSTICS MARKET, BY GEOGRAPHY, 20142022 ($MILLION)
  • TABLE 27: TRANSPLANT DIAGNOSTICS MARKET, BY ORGAN TYPE, 20142022 ($MILLION)
  • TABLE 28: TRANSPLANT DIAGNOSTICS ORGAN TYPE MARKET, BY GEOGRAPHY, 20142022 ($MILLION)
  • TABLE 29: TRANSPLANT DIAGNOSTICS MARKET FOR KIDNEY, BY GEOGRAPHY, 20142022 ($MILLION)
  • TABLE 30: TRANSPLANT DIAGNOSTICS MARKET FOR LIVER, BY GEOGRAPHY, 20142022 ($MILLION)
  • TABLE 31: TRANSPLANT DIAGNOSTICS MARKET FOR HEART, BY GEOGRAPHY, 20142022 ($MILLION)
  • TABLE 32: TRANSPLANT DIAGNOSTICS MARKET FOR LUNGS, BY GEOGRAPHY, 20142022 ($MILLION)
  • TABLE 33: TRANSPLANT DIAGNOSTICS MARKET FOR PANCREAS, BY GEOGRAPHY, 20142022 ($MILLION)
  • TABLE 34: WORLD TRANSPLANT DIAGNOSTICS MARKET FOR OTHER ORGANS, BY GEOGRAPHY, 20142022 ($MILLION)
  • TABLE 35: WORLD TRANSPLANT DIAGNOSTICS MARKET, BY TYPE OF SCREENING, 20142022 ($MILLION)
  • TABLE 36: WORLD TRANSPLANT DIAGNOSTICS SCREENING MARKET, BY GEOGRAPHY, 20142022 ($MILLION)
  • TABLE 37: WORLD PRE-SCREENING MARKET, BY GEOGRAPHY, 20142022 ($MILLION)
  • TABLE 38: WORLD POST-SCREENING MARKET, BY GEOGRAPHY, 20142022 ($MILLION)
  • TABLE 39: WORLD TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 20142022 ($MILLION)
  • TABLE 40: NORTH AMERICAN TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 20142022 ($MILLION)
  • TABLE 41: NORTH AMERICAN TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 20142022 ($MILLION)
  • TABLE 42: EUROPEAN TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 20142022 ($MILLION)
  • TABLE 43: EUROPEAN TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 20142022 ($MILLION)
  • TABLE 44: ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT, 2014-2022 ($MILLION)
  • TABLE 45: ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 20142022 ($MILLION)
  • TABLE 46: LAMEA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT, 20142022 ($MILLION)
  • TABLE 47: LAMEA TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 20142022 ($MILLION)
  • TABLE 49: IMMUCOR: OPERATING SEGMENTS
  • TABLE 51: BIO-RAD: OPERATING SEGMENTS
  • TABLE 53: THERMO FISHER: OPERATING SEGMENTS
  • TABLE 55: ROCHE: OPERATING SEGMENTS
  • TABLE 57: ILLUMINA: OPERATING SEGMENTS
  • TABLE 59: ABBOTT: OPERATING SEGMENTS
  • TABLE 61: SIGMA-ALDRICH: OPERATING SEGMENTS
  • TABLE 63: QIAGEN N.V.: OPERATING SEGMENTS
  • TABLE 66: DIASORIN: OPERATING SEGMENTS

List of Figures

  • FIG. 1: TOP INVESTMENT POCKETS IN WORLD TRANSPLANT DIAGNOSTICS MARKET
  • FIG. 2: TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (20112016)
  • FIG. 3: TOP WINNING STRATEGIES: NATURE & TYPE
  • FIG. 4: PORTERS FIVE FORCES ANALYSIS
  • FIG. 5: TRANSPLANT DIAGNOSTICS MARKET TOP PLAYER POSITIONING, 2015
  • FIG. 6: WORLD GERIATRIC POPULATION, BY REGION, 2015
  • FIG. 7: TRANSPLANT PROCEDURES IN THE U.S., BY AGE, 2015
  • FIG. 8: WAITING LIST IN U.S. FOR ORGAN TRANSPLANTATION BY TYPE OF ORGAN
  • FIG. 9: U.S.: TRANSPLANT DIAGNOSTICS MARKET, 20142022 ($MILLION)
  • FIG. 10: CANADA: TRANSPLANT DIAGNOSTICS MARKET, 20142022 ($MILLION)
  • FIG. 11: MEXICO: TRANSPLANT DIAGNOSTICS MARKET, 20142022 ($MILLION)
  • FIG. 12: U.K.: TRANSPLANT DIAGNOSTICS MARKET, 20142022 ($MILLION)
  • FIG. 13: GERMANY: TRANSPLANT DIAGNOSTICS MARKET, 20142022 ($MILLION)
  • FIG. 14: FRANCE: TRANSPLANT DIAGNOSTICS MARKET, 20142022 ($MILLION)
  • FIG. 15: SPAIN: TRANSPLANT DIAGNOSTICS MARKET, 20142022 ($MILLION)
  • FIG. 16: ITALY: TRANSPLANT DIAGNOSTICS MARKET, 20142022 ($MILLION)
  • FIG. 17: TURKEY: TRANSPLANT DIAGNOSTICS MARKET, 20142022 ($MILLION)
  • FIG. 18: REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET, 20142022 ($MILLION)
  • FIG. 19: AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET, 20142022 ($MILLION)
  • FIG. 20: SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET, 20142022 ($MILLION)
  • FIG. 21: NEW ZEALAND: TRANSPLANT DIAGNOSTICS MARKET, 20142022 ($MILLION)
  • FIG. 22: CHINA: TRANSPLANT DIAGNOSTICS MARKET, (20142022) ($MILLION)
  • FIG. 23: JAPAN: TRANSPLANT DIAGNOSTICS MARKET, 20142022 ($MILLION)
  • FIG. 24: REST OF ASIA-PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, (20142022) ($MILLION)
  • FIG. 25: BRAZIL: TRANSPLANT DIAGNOSTICS MARKET, 20142022 ($MILLION)
  • FIG. 26: ISRAEL: TRANSPLANT DIAGNOSTICS MARKET, 20142022 ($MILLION)
  • FIG. 27: IRAN: TRANSPLANT DIAGNOSTICS MARKET, 20142022 ($MILLION)
  • FIG. 28: SAUDI ARABIA TRANSPLANT DIAGNOSTICS MARKET, 20142022 ($MILLION)
  • FIG. 29: REST OF LAMEA TRANSPLANT DIAGNOSTICS MARKET, 20142022 ($MILLION)
  • FIG. 30: IMMUCOR: REVENUE, 20132015, ($MILLION)
  • FIG. 31: IMMUCOR: REVENUE, BY BUSINESS SEGMENT, 2015(%)
  • FIG. 32: IMMUCOR: REVENUE, BY GEOGRAPHY, 2015, (%)
  • FIG. 33: BIO-RAD: SALES, 20132015, ($MILLION)
  • FIG. 34: BIO-RAD: SALES, BY BUSINESS SEGMENT, 2015 (%)
  • FIG. 35: BIO-RAD: SALES, BY GEOGRAPHY, 2015(%)
  • FIG. 36: THERMO FISHER: REVENUE, 20132015 ($MILLION)
  • FIG. 37: THERMO FISHER: REVENUE, BY BUSINESS SEGMENT, 2015, (%)
  • FIG. 38: THERMO FISHER: REVENUE, BY GEOGRAPHY, 2015 (%)
  • FIG. 39: ROCHE: REVENUE, 20132015 ($MILLION)
  • FIG. 40: ROCHE: REVENUE, BY BUSINESS SEGMENT, 2015(%)
  • FIG. 41: ROCHE: REVENUE, BY GEOGRAPHY, 2015(%)
  • FIG. 42: ILLUMINA: REVENUE, 20132015 ($MILLION)
  • FIG. 43: ILLUMINA: REVENUE, BY SEGEMNT, 2015 (%)
  • FIG. 44: ILLUMINA: REVENUE, BY GEOGRAPHY, 2015 (%)
  • FIG. 45: ABBOTT: REVENUE, 20132015 ($MILLION)
  • FIG. 46: ABBOTT: REVENUE, BY BUSINESS SEGMENT, 2015 (%)
  • FIG. 47: ABBOTT: REVENUE, BY GEOGRAPHY, 20132015 ($MILLION)
  • FIG. 48: SIGMA-ALDRICH: REVENUE, 20132014 ($MILLION)
  • FIG. 49: SIGMA-ALDRICH: REVENUE, BY BUSINESS UNITS, 2014 (%)
  • FIG. 50: SIGMA-ALDRICH: REVENUE, BY GEOGRAPHY, 2014 (%)
  • FIG. 51: QIAGEN N.V.: REVENUE, 20132015 ($MILLION)
  • FIG. 52: QIAGEN N.V.: REVENUE, BY BUSINESS SEGMENT, 2015 (%)
  • FIG. 53: QIAGEN N.V.: REVENUE, BY GEOGRAPHY, 2015 (%)
  • FIG. 54: DIASORIN: REVENUE, 20132015 ($MILLION)
  • FIG. 55: DIASORIN: REVENUE, BY GEOGRAPHY, 2015 (%)
Back to Top